Here is a brief preview of this blast: Recently, Novartis reported (press release) that their Ph3 BELINDA study evaluating Kymriah (CD19 CAR-T) in 2L NHL did not meet its primary endpoint (EFS) compared to the standard of care (SoC). Below, Celltelligence provides insights on how Novartis’s trial design could have potentially contributed to BELINDA’s failure, while discussing alternative approaches that Novartis may take to stay in the 2L DLBCL setting.

About The Author

The Celltelligence Team

|

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.